Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00520949
Status:
COMPLETED
Last Update Posted:
2009-04-08
First Post:
2007-08-24
Brief Title:
Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection
Sponsor:
Aga Khan University
Organization:
Aga Khan University
Study Overview
Official Title:
Quadruple Therapy Using Esomeprazole Colloidal Bismuth Subcitrate Amoxicillin-Clavulanate and Furazolidone in Patients Who Failed to Eradicate H Pylori With Triple Therapy
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
QT-Hp
Brief Summary:
Triple therapy a combination of proton pump inhibitor with two antibiotics is the gold standard for anti-Helicobacter pylori treatment Usual antibiotics are clarithromycin and either amoxicillin or one of the nitroimidazoles metronidazole However there is an increasing evidence of H pylori resistance to classical triple therapy Another reason for this failure being low patient compliance with treatment A regimen useful in one geographical area may not be effective or practical in another area The aim of this study was to eradicate H pylori infection resistant to triple therapy establish the efficacy and safety of a 14-day therapeutic regimen to eradicate of H pylori in patients who have failed with the classical triple therapy omeprazole clarithromycin and amoxicillin given for 14 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None